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ABSTRACT
Aims To estimate the influence of non-medical use of prescription opioids (NMUPO) on heroin initiation among US
veterans receiving medical care. Design Using a multivariable Cox regression model, we analyzed data from a
prospective, multi-site, observational study of HIV-infected and an age/race/site-matched control group of HIV-
uninfected veterans in care in the United States. Approximately annual behavioral assessments were conducted and
contained self-reported measures of NMUPO and heroin use. Setting Veterans Health Administration (VHA) infectious
disease and primary care clinics in Atlanta, Baltimore, New York, Houston, Los Angeles, Pittsburgh andWashington, DC.
Participants A total of 3396 HIV-infected and uninfected patients enrolled into the Veterans Aging Cohort Study who
reported no life-time NMUPO or heroin use, had no opioid use disorder diagnoses at baseline and who were followed
between 2002 and 2012. Measurements The primary outcome measure was self-reported incident heroin use and
the primary exposure of interest was new-onset NMUPO. Our final model was adjusted for socio-demographics, pain
interference, prior diagnoses of post-traumatic stress disorder and/or depression and self-reported other substance use.
Findings Using a multivariable Cox regression model, we found that non-medical use of prescription opioids NMUPO
was associated positively and independently with heroin initiation [adjusted hazard ratio (AHR) = 5.43, 95% confidence
interval (CI) = 4.01, 7.35]. Conclusions New-onset non-medical use of prescription opioids (NMUPO) is a strong risk
factor for heroin initiation among HIV-infected and uninfected veterans in the United States who reported no previous
history of NMUPO or illicit opioid use.
Keywords Heroin, longitudinal study, non-medical prescription drug use, opioid-related disorders, polysubstance use,
veterans.
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INTRODUCTION
Heroin use and opioid use disorders are serious public
health problems [1]. The US Centers for Disease Control
and Prevention (CDC) reported that the total number of
heroin-attributable overdose deaths increased fivefold from
2001 to 2013, with 8257 heroin-related deaths in 2013
alone [2]. The substantial increase in heroin use and
heroin-attributable overdose rates may be linked to the
growth in sales, use and misuse of prescription opioids
[3]. During the last decade, the number of opioid prescrip-
tions dispensed in the United States increased by 48%
[4,5]. Concomitantly, the non-medical use of prescription
opioids (NMUPO)—defined operationally in the National
Survey on Drug Use and Health as the use of prescription
opioids ‘without a prescription of the individual’s own or
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simply for the experience or feeling the drugs cause’—is
increasingly common [6]. The last 15 years has seen sharp
rises in NMUPO [6–8], with 4.5 million individuals
reporting NMUPO in the past month in 2013 [9].
Canadian data estimate that approximately 4.8% of the
general population used prescription opioids non-medically
in 2009 and as the demand for prescription opioids has
increased so, too, has the availability of diverted
prescription opioids [10]. In the past two decades, the use
of opioids has also increased significantly in Europe [11].
In particular, there is a high prevalence of misuse of
diverted opioids among drug-using populations in England
and Scotland [11].
People who engage in NMUPO may be at a higher
risk for transitioning to heroin use, in part because her-
oin has become more accessible and less expensive than
prescription opioids in many US settings [12–14]. A
nationally representative survey found that four out of
five recent heroin initiates reported prior NMUPO, and
the rate of heroin initiation among prior non-medical
prescription opioid users was approximately 19 times
greater than those who did not report non-medical use
[15]. Heroin initiation is particularly troubling because
of the additional risks associated with heroin use, includ-
ing unknown purity and contaminants, overdose and
injection-associated infections and vascular disease
[12,16]. Transition from NMUPO to heroin also repre-
sents an increasingly prominent pathway leading to
opioid-related mortality [17].
US military veterans represent a particularly high-risk
population for illicit substance use and abuse [18–20].
Chronic pain is a significant problem among veterans
[21], and is treated commonly with opioid analgesics
[22]. Veterans also have high rates of mental health
conditions that further increase the risk for NMUPO [23].
However, whether NMUPO plays a role in veterans’ risk
for initiating heroin use is poorly understood, particularly
in those veterans from newer eras, including Operation
Enduring Freedom and Operation Iraqi Freedom [24].
To address this critical public health problem, we
examined the relationship between new-onset NMUPO
and heroin initiation among veterans. We aimed to: (1)
identify risk factors for heroin initiation among participants
enrolled into the Veterans Aging Cohort Study; (2)
calculate the crude incidence rate of heroin initiation in
this high risk population; and (3) compare the hazard of
heroin initiation between participants with self-reported
NMUPO and no prior NMUPO.
METHODS
Data sources
This research utilizes data from the Veterans Aging Cohort
Study (VACS); detailed data collection and survey
methodology for VACS are described elsewhere [25–31].
The VACS is an ongoing, prospective cohort study of
HIV-infected and uninfected veterans receiving medical
care at eight Veterans Health Administration (VHA) sites
located throughout the United States. Since June 2002,
VACS has enrolled more than 7000 patients from the
infectious disease or general medical clinics in Atlanta,
Baltimore, Houston, Los Angeles, Pittsburgh, Washington
DC and multiple sites in New York City. Participants in
VACS are similar to other veterans receiving care within
the VA, with the exception of participants being older
and more predominantly black [30]. This comprehensive,
longitudinal database contains variables from surveys com-
pleted approximately every 18months, available from2002
to 2012. The survey data are also linked to robust VA elec-
tronic medical records (EMR) containing data on prescribed
medications, medical and substance use diagnoses and
laboratory results for each patient. The VACS was approved
by the institutional review boards at each participating
VHA Medical Center and affiliated academic institutions.
Participant eligibility
The flow-chart illustrating the selection of eligible
participants is illustrated in Fig.1. Of 7324 potentially
Figure 1 Flow-chart of eligible Veterans Aging Cohort Study (VACS)
participants, 2002–12 NMUPO=non-medical use of prescription opioids
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eligible VACS participants, 2792 (38.1%)were excluded, as
they reported ‘yes’ to ever using a prescription opioid
non-medically or heroin use at baseline. Of these
participants, we excluded those who reported any injection
drug use at baseline, or who were previously diagnosed
with opioid dependence based on linked EMR records
(ICD-9 code 304.0) (n = 399). Finally, we excluded partic-
ipants whoweremissingor had invalid NMUPO and heroin
use responses in all five follow-up surveys (n= 186) or only
completed the baseline survey (n = 551). Using data from
the VHA Patient Treatment File, the Beneficiary Identifica-
tion Records Locating System (which tracks VHA death
benefits, the Medicare Vital Status file and the Social Secu-
rity National Death index, we identified 203 (36.9%)
deaths among those participants who only completed the
baseline survey. We compared the characteristics of those
who did not complete at least one follow-up visit due to
death or other reasons with those who were eligible (see
Supporting information). We accounted for biases arising
from potential differential loss to follow-up in weighted sta-
tistical analyses (see below). The final analytical sample
consisted of 3396 veterans.
Measures
We operationalized the main exposure of NMUPO using
responses to two different survey questions. In the first
two of five survey waves, participants were shown a list of
the following substances: ‘marijuana, cocaine/crack,
stimulants, heroin, and prescription opioids (morphine,
codeine, Vicodin, Percocet, OxyContin)’, and asked: ‘For
each of the following drugs, please fill in the oval that best
indicates how often in the past 12 months you have used
each drug’. Those participants who reported any use of
prescription opioids were categorized as reporting NMUPO.
In the final three follow-up survey waves participants were
asked: ‘Now think only about the past 12 months. On
average, how many days each week in the past 12 months
did you use any prescription pain reliever that was not
prescribed for you or that you took only for the experience
or feeling that it caused?’ [32]. Again, participants
reporting any frequency of use were categorized as
reporting NMUPO. Participants who experienced the
outcome of interest (i.e. heroin initiation) in the same year
that they initiated NMUPO were included in the analysis;
thus, new-onset NMUPO was considered to occur prior to
or concurrently with heroin initiation.
Self-reported heroin initiationwas ascertained based on
respondent endorsement of following time-updated survey
item: ‘How often in the past year have you used each drug
—heroin?’. A heroin initiation event was defined as change
in respondent’s answer to the previous survey question,
from ‘Never’ to a response indicating some frequency of
heroin use in the previous year.
Selection of other independent variables and potential
confounders of the relationship between NMUPO and
heroin initiation were chosen for analysis based on the
extant literature [22,28,33–36]. Demographic and clinical
characteristics were ascertained from the baseline survey
data and included age, sex, race, marital status and gross
annual income. HIV status was identified using VA
Immunology Case Registry and hepatitis C virus status
was determined using ICD-9 codes and laboratory data.
Previous post-traumatic stress disorder (PTSD) and
depression diagnoses were ascertained from the following
questions: ‘Has the doctor ever told you that you have
PTSD?’ and ‘Has the doctor ever told you that you have
depression?’. Pain interference in daily life was ascertained
from responses to the following time-updated survey item:
‘During the past 4 weeks, how much did pain interfere
with your normal work (including both work outside the
home and housework)?’ [37]. The response options for this
question included a scale from ‘not at all’ to ‘extremely’,
which we dichotomized into ‘no interference’ (‘not at all’)
and ‘any interference’ (any other response). Past-year use
of marijuana, cocaine and methamphetamines was
dichotomized as yes/no. Alcohol use was characterized
using the Alcohol Use Disorders Identification Test
(AUDIT); a score of 4 and above indicated unhealthy
alcohol use for men, and a threshold of 3 for women
[38]. Responses to questions regarding substance use
(including marijuana, cocaine and methamphetamines),
unhealthy alcohol use, prior PTSD and depression
diagnoses and pain interference in daily life were updated
at each survey and were considered time-dependent
covariates. Consistent with prior methods, receipt of out-
patient prescribed opioids from the VHA was ascertained
from linked pharmacy records, and long-term prescription
opioid use was defined as ≥ 90 days of continuous use
allowing for a 30-day gap between fill and refill
[27,29,39]. We created a time-updated variable for
past-year receipt of prescription opioids for each wave of
data, and categorized it into ‘none’, ‘short-term’ and
‘long-term’.
Statistical analyses
First, we used χ2 tests to examine the baseline correlates of
heroin initiation. Additionally, in a post-hoc analysis, we
examined interaction terms between NMUPO and race.
Next, unadjusted Kaplan–Meier analysis and the log-rank
test were used to calculate the incidence of heroin
initiation and compare time to heroin use, stratifying by
prior or concurrent NMUPO.
To analyze the factors associated with heroin initiation,
we used Cox proportional hazards regression to estimate
crude hazard ratios (CHRs) and 95% confidence intervals
(CI) for each variable. To determine the independent
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relationship between new-onset NMUPO and heroin
initiation, we then constructed a multivariable Cox model,
including all variables assessed in bivariable analyses. All
variables were found to meet the proportional hazards
assumption for the Cox regression models (i.e. none
exhibited significant deviance from this assumption at
P < 0.05) [40].
We created inverse probability of censoring weights
(IPCWs) to account for potential biases arising from
differential dropout [41]. The use of IPCW re-weights the
sample such that the contribution of participants who
remain in the study, but who share characteristics of those
who drop out, are inflated [42]. Weights were obtained
through fitting a weighted pooled logistic regression model
for dropout, including baseline and time-varying predictors
of dropping out. We included a robust sandwich estimator
in all Cox regression models to account for potential
clustering heterogeneity by study site [43]. Analyses were
conducted using SAS version 9.4.
Sensitivity analysis
In order to assess the validity of our exclusion criteria and
ensure that our sample was restricted to heroin-naive
participants we re-ran the adjusted Cox regression model,
excluding those participants who were HCV-positive at
baseline (n=701), under the assumption that themajority
could have contracted HCV via injecting.
RESULTS
Sample composition
The baseline demographic, clinical and substance use
characteristics of the 3396 eligible VACS participants are
described in Table 1. The mean age was 49.7 [standard
deviation (SD) = 10.6], 2106 (62.5%) were black and
327 (9.7%) were Hispanic. Approximately 1500 partici-
pants (45%) were HIV-infected. At baseline, 102 (3.8%)
participants had a past-year opioid prescription from the
VHA. Table 1 describes the characteristics of participants
who reported new-onset NMUPO during the study.
Past-year stimulant and past-year cocaine use were
associated significantly with NMUPO in our study sample
(P < 0.05). However, receipt of a prescription opioid from
the VHA was not associated significantly with NMUPO.
There were no substantial differences between the
distribution of baseline characteristics among those
participants who did not complete at least one follow-up
visit or were missing exposure data and those participants
who were eligible for our study (see Supporting
information, Table S1).
The mean proportion of participants who initiated or
continued non-medical use of prescription opioids across
all follow-up waves after baseline was 6.9%. There was
no clear secular trend in the proportion of participants
who reported NMUPO over time (Mantel–Haenszel test
for trend P = 0.208).
Risk factors for heroin initiation
Of the total sample, 500 (14.7%) participants initiated
heroin use during the 10-year study period. Being black,
male, 43–49 years of age, less educated and having a lower
income were associated significantly with heroin initiation
(all P < 0.001). Marijuana, cocaine, stimulant and
unhealthy alcohol use in the past year were associated
significantly with heroin initiation. (all P < 0.05, see
Table 2).
Figure 2 illustrates the Kaplan–Meier curves for time to
heroin initiation, which differed significantly between
participants who reported prior/concurrent NMUPO and
non-users; the log-rank test was significant at P < 0.001.
Of the 500 heroin initiates, 77% reported previous or
concurrent NMUPO (P< 0.001). The crude incidence rate
for heroin initiation in our entire study sample was 2.60
per 100 person-years, while the crude incidence rate for
heroin was 4.82 per 100 person-years among those
reporting NMUPO and 1.02 per 100 person-years among
non-users, respectively (P < 0.001). Of the participants
who reported new-onset NMUPO, 27.3% initiated heroin
by the end of the 10-year study period. (see Supporting
information, Figure S1), depicts the proportion initiating
heroin use among participants who engaged in NMUPO
at each time-point.
The results from both the unadjusted and adjusted Cox
regression models using IPCW are shown in Table 3. The
crude hazard for heroin initiation was significantly higher
for males than for females, and the crude hazards for black
and Hispanic participants were significantly higher than
for white participants. Those participants with a previous
PTSD or depression diagnoses had a significantly higher
hazard of heroin initiation when compared to those
without these diagnoses. The crude hazard ratios of heroin
initiation among past-year marijuana, stimulant and
cocaine users were also significantly higher than those
participants who reported no use. For participants
reporting concurrent or prior NMUPO versus none, the
crude hazard ratio was 5.15 [95% confidence interval
(CI) = 3.89–6.81].
In the multivariable Cox regression analysis, NMUPO
remained associated positively and significantly with
heroin initiation [adjusted hazard ratio (AHR) = 5.43,
95% CI = 4.01–7.35]. In the fully adjusted and weighted
model, those who reported stimulant use and cocaine use
in the last year had AHRs of 2.12 (95% CI = 1.05–4.27)
and 1.74 (95% CI = 1.10–2.76), respectively, compared
to those participants who reported no past-year use.
Receipt of a short-term opioid prescription from the VHA
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Table 1 Baseline characteristics associated with new-onset non-medical use of prescription opioids among veterans participating in
Veterans Aging Cohort Study (VACS), 2002–12.
Reported NMUPO
Characteristic Total (%) (N = 3396) Yes (%) (n = 1416) No (%) (n = 1980) P-valuea
Sex 0.468
Male 3171 (93.4) 1317 (41.5) 1854 (58.5)
Female 225 (6.6) 99 (44.0) 126 (56.0)
Age (years) 0.001
≤ 42 846 (24.9) 356 (42.1) 490 (57.9)
43–49 880 (25.9) 387 (44.0) 493 (56.0)
50–56 884 (26.0) 392 (44.3) 492 (55.7)
≥ 57 786 (23.1) 281 (35.8) 505 (64.2)
HIV < 0.001
Yes 1539 (45.3) 694 (45.1) 845 (54.9)
No 1857 (54.7) 722 (38.9) 1135 (61.1)
HCV 0.034
Yes 701 (20.6) 317 (45.2) 384 (54.8)
No 2695 (79.4) 1099 (40.8) 1596 (59.2)
Race < 0.001
White 808 (24.0) 430 (53.2) 378 (46.8)
Black 2106 (62.5) 800 (38.0) 1306 (62.0)
Hispanic 327 (9.7) 106 (32.4) 221 (67.6)
Other 128 (3.8) 57 (44.5) 71 (55.5)
Education 0.001
High school or less 1301 (38.3) 499 (38.4) 802 (61.6)
Some college or greater 2095 (61.7) 917 (43.8) 1178 (56.2)
Gross annual income 0.711
< $6000 532 (16.2) 220 (41.4) 312 (58.7)
$6000–11999 695 (21.2) 295 (42.5) 400 (57.6)
$12000–24 999 856 (26.1) 344 (40.2) 512 (59.8)
$25000–49 999 815 (24.8) 474 (58.2) 341 (41.8)
≥ $50 000 383 (11.7) 170 (44.4) 213 (55.6)
Marital status < 0.425
Married/living with partner 1128 (33.5) 481 (42.6) 647 (57.4)
Divorced/separated/widowed 1257 (37.3) 508 (40.4) 749 (59.6)
Never married 984 (29.2) 421 (42.8) 563 (57.2)
Pain interference in daily life < 0.001
Yes 1966 (58.2) 955 (48.6) 1011 (51.4)
No 1415 (41.9) 457 (32.3) 958 (67.7)
Opioid Rx, past year 0.330
None 3265 (96.1) 1357 (41.6) 1908 (58.4)
Short-term 102 (3.0) 43 (42.2) 59 (57.8)
Long-term 29 (0.9) 16 (55.2) 13 (44.8)
Marijuana use, past year 0.165
Yes 654 (19.3) 289 (44.2) 365 (55.8)
No 2730 (80.7) 1125 (41.2) 1605 (58.8)
Stimulant use, past year 0.012
Yes 53 (1.6) 31 (58.5) 22 (41.5)
No 3341 (98.4) 1384 (41.4) 1957 (58.6)
Cocaine use, past year < 0.024
Yes 421 (12.5) 197 (46.8) 224 (53.2)
No 2958 (87.5) 1213 (41.0) 1745 (59.0)
Unhealthy alcohol use, past year (AUDIT-C score ≥ 3 or 4) 0.239
Yes 864 (25.4) 375 (43.4) 489 (56.6)
No 2532 (74.6) 1041 (41.1) 1491 (58.9)
aFrom χ
2
tests. HIV = human immunodeficiency virus; HCV = hepatitis C virus; AUDIT = Alcohol Use Disorders Identification Test; NMUPO = non-medical
use of prescription opioids.
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Table 2 Baseline characteristics associated with heroin initiation among veterans participating in Veterans Aging Cohort Study (VACS),
2002–12.
Initiated heroin
Characteristic Total (%) (N = 3396) Yes (%) (n = 500) No (%) (n = 2896) P-valuea
Sex < 0.001
Male 3171 (93.4) 487 (15.4) 2684 (84.6)
Female 225 (6.6) 13 (5.8) 212 (94.2)
Age (years) < 0.001
≤ 42 846 (24.9) 105 (12.4) 741 (87.6)
43–49 880 (24.9) 186 (21.1) 694 (78.9)
50–56 884 (26.0) 138 (15.6) 746 (84.4)
≥ 57 786 (23.1) 71 (9.0) 715 (91.0)
HIV < 0.001
Yes 1539 (45.3) 279 (18.1) 1260 (81.9)
No 1857 (54.7) 221 (11.9) 1636 (88.1)
HCV < 0.001
Yes 701 (20.6) 170 (24.3) 531 (75.8)
No 2695 (79.4) 330 (12.2) 2365 (87.8)
Race < 0.001
White 808 (24.0) 76 (9.4) 732 (90.6)
Black 2106 (62.5) 363 (17.2) 1743 (82.8)
Hispanic 327 (9.7) 38 (11.6) 289 (88.4)
Other 128 (3.8) 22 (17.2) 106 (82.8)
Education < 0.001
High school or less 1301 (38.3) 235 (18.1) 1066 (81.9)
Some college or greater 2095 (61.7) 265 (12.7) 1830 (87.3)
Gross annual income < 0.001
< $6000 532 (16.2) 116 (21.8) 416 (78.2)
$6000–11999 695 (21.2) 128 (18.4) 567 (81.6)
$12 000–24999 856 (26.1) 119 (13.9) 737 (86.1)
$25 00–49999 815 (24.8) 94 (11.5) 721 (88.5)
≥ $50 000 383 (11.7) 28 (7.3) 355 (92.7)
Marital status < 0.001
Married/living with partner 1128 (33.5) 126 (11.2) 1002 (88.8)
Divorced/separated/widowed 1257 (37.3) 200 (15.9) 1057 (84.1)
Never married 984 (29.2) 171 (17.4) 813 (82.6)
Pain interference in daily life 0.115
Yes 1966 (58.2) 305 (15.5) 1661 (84.5)
No 1415 (41.9) 192 (13.6) 1223 (86.4)
Opioid Rx, past year 0.565
None 3265 (96.1) 481 (14.7) 2784 (85.3)
Short-term 102 (3.0) 13 (12.8) 89 (87.2)
Long-term 29 (0.9) 6 (20.7) 23 (79.3)
Marijuana use, past year < 0.001
Yes 654 (19.3) 126 (19.3) 528 (80.7)
No 2730 (80.7) 373 (13.7) 2357 (86.3)
Stimulant use, past year 0.005
Yes 53 (1.6) 15 (28.3) 38 (71.7)
No 3341 (98.4) 485 (14.5) 2856 (85.5)
Cocaine use, past year < 0.001
Yes 421 (12.5) 144 (34.2) 277 (65.8)
No 2958 (87.5) 354 (12.0) 2604 (88.0)
Unhealthy alcohol use, past year (AUDIT-C score ≥ 3 or 4) 0.006
Yes 864 (25.4) 152 (17.6) 712 (82.4)
No 2532 (74.6) 348 (13.7) 2184 (86.3)
aFrom χ
2
tests; HIV = human immunodeficiency virus; HCV = hepatitis C virus; AUDIT = Alcohol Use Disorders Identification Test.
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increased the hazard of heroin initiation by 65%
(AHR = 1.65, 95% CI = 1.43–1.94) in our fully adjusted
model. Other factors associated independently with heroin
initiation are shown in Table 3. In post-hoc analyses, the
effect of NMUPO on heroin initiation varied significantly
by race: AHR = 5.46, 95% CI = 3.72–8.02 for black
participants, AHR = 7.67, 95% CI = 4.23–13.88 for
Hispanic participants and AHR = 4.89, 95%
CI = 2.52–9.37 for white participants.
Sensitivity analysis
After removing the 701 (20.6%) HCV-infected partici-
pants, the association between NMUPO and heroin
initiation remained similar to that in the original model.
Specifically, NMUPO had an AHR of 6.21 (95%
CI = 4.54–8.51).
DISCUSSION
In this study, we characterized the relationship between
new-onset NMUPO and heroin initiation in a population
of US military veterans receiving medical care in the
VHA. Our results indicate a strong association between
prior or concurrent NMUPO and initiation of heroin use.
The observed effect was robust to covariate adjustment
and a sensitivity analysis. To our knowledge, this study is
the first to demonstrate an effect of NMUPO on risk for
heroin initiation prospectively among veterans receiving
medical care.
Given these findings, it is important for clinicians to be
cognizant of risk factors that are associated with
transitioning to heroin initiation among veterans and
other high-risk populations. Our results, corroborated by
other literature [12,44,45], indicate that being a racial
minority, having lower education and income levels and
reporting other substance use (particularly cocaine,
stimulant and alcohol use) are all associated with heroin
initiation. HIV and HCV infection were both predictors of
heroin initiation in our fully adjusted model. This is cause
for concern, as the transmission of infectious diseases
may occur as a result of initiation of injection of heroin or
prescription opioids [46]. Finally, the differences in the
effect of NMUPO on heroin initiation between black, white
and Hispanic participants may be due to disparities in
access to appropriate pain management and/or reduced
access to opioid prescriptions among minorities [47].
Future research is needed to explore further the role of
reduced access to prescription opioids as a risk factor for
heroin initiation in minority populations.
Our study suggests that the identification and
treatment of non-medical prescription opioid use in a
veteran population could be an important strategy for
preventing heroin initiation. Guidelines, including those
developed by the Department of Veterans Affairs and
Department of Defense, recommend that prescribers of
long-term opioids re-assess treatment effectiveness, adverse
effects and adherence to therapy regularly; monitor for
evidence of opioid misuse or substance abuse; and consider
written treatment agreements and periodic urine drug
testing [48]. It is important that continued attention be
given to the development and refinement of screening
procedures to identify problematic prescription opioid use
among veterans receiving care.
Our study eligibility criteria resulted in the exclusion of
a number of participants with opioid prescriptions from the
VHA. For example, participantswho reported any injection
drug use and participants who had a previous diagnosis of
an opioid dependence at baseline were excluded, both of
which are factors associated with prescription opioid
Figure 2 Relationship between prior/concur-
rent non-medical use of prescription opioids
(NMUPO) and first-time initiation of heroin
among Veterans Aging Cohort Study (VACS)
participants (2002–12)
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receipt in the VACS sample [39]. For this reason, the
proportion of the study sample who received an opioid
prescription may be lower than the prevalence of opioid
prescriptions in other VA populations, which averaged
approximately 7.7%, with a range of 0.26–21.8% in
2012 [49].
None the less, the finding that receipt of a short-term
opioid prescription was associated independently with an
increased hazard of heroin initiation adds to the literature
demonstrating a strong correlation between therapeutic
exposure to opioid analgesics and their abuse [50]
Collectively, these results supported recently published
CDC guidelines recommending that, when opioids are used
to treat acute pain, physicians should prescribe no greater
quantity than needed for the expected duration of the
severe pain [51] These strategies may also reduce the total
volume of diverted opioids for non-medical use. Finally, our
findings suggest that clinicians should evaluate risk factors
for heroin initiation (e.g. history of a substance use
disorder) prior to initiating opioid therapy. The potential
to reduce NMUPO and subsequent opioid use disorders
and heroin use by reducing the prescribing of opioids is
an especially important consideration for those countries
where opioid prescribing is rising. If the rates of opioid
prescribing and NMUPO continue to increase in Europe,
future regulatory responsesmay be needed to prevent rates
of opioid misuse that are seen in North America [52,53].
Our study had a number of limitations. First, our results
may not be generalizable to all veterans receiving care in
the VHA. Due to its design, the study enrolled individuals
who are probably at higher risk for heroin initiation than
the general veteran population (e.g. those with HIV
Table 3 Inverse probability weighted Cox proportional hazard model of factors associated with time to self-reported incident heroin use
among non-medical use of prescription opioids (NMUPO)/heroin-naïive veterans participating in Veterans Aging Cohort Study (VACS),
2002–12d.
Characteristic Unadjusted HRd (95% CI) P - value Adjusted HRd (95% CI) P - value
NMUPO (any NMUPO versus none)c 5.15 (3.89–6.81) < 0.001 5.43 (4.01–7.35) < 0.001
Sex (ref: Female)b 2.91 (1.18–7.19) 0.021 2.61 (1.08–6.29) 0.033
Age (ref: ≤ 42 years)b
43–49 years 1.79 (1.56–2.07) < 0.001 1.67 (1.44–1.93) < 0.001
50–6 years 1.36 (1.20–1.53) < 0.001 1.33 (1.16–1.52) < 0.001
≥ 57 years 0.76 (0.54–1.05) 0.093 0.95 (0.64–1.42) 0.817
HIV (infected versus uninfected)b 1.65 (1.44–1.89) < 0.001 1.17 (1.04–1.32) 0.012
HCV (infected versus uninfected)b 2.19 (1.63–2.95) < 0.001 1.46 (1.24–1.72) < 0.001
Race (ref: white)b
Black 1.88 (1.42–2.49) < 0.001 1.95 (1.46–2.61) < 0.001
Hispanic 1.39 (1.08–1.79) 0.010 1.49 (1.09–2.03) 0.011
Other 2.18 (1.85–2.57) < 0.001 1.86 (1.49–2.30) < 0.001
Education (ref: high school or less)b
Some college or greater 0.67 (0.61–0.75) < 0.001 0.72 (0.59–0.87) < 0.001
Gross annual income (ref: <$6000)b
$6000–11999 0.79 (0.59–1.07) 0.131 1.01 (0.74–1.37) 0.956
$12 000–24999 0.58 (0.49–0.67) < 0.001 0.88 (0.71–1.10) 0.268
$25 000–49999 0.50 (0.35–0.70) < 0.001 0.78 (0.63–0.97) 0.028
≥ $50 000 0.28 (0.16–0.49) < 0.001 0.52 (0.30–0.90) 0.019
Marital status (ref: married/living with partner)b
Divorced/separated/widowed 1.50 (1.19–1.90) < 0.001 1.14 (0.86–1.51) 0.363
Never married 1.74 (1.32–2.31) < 0.001 1.36 (0.99–1.86) 0.061
PTSD (ever diagnosis versus none)a 1.70 (1.43–2.03) < 0.001 1.25 (1.02–1.54) 0.031
Depression (ever diagnosis versus none)a 1.42 (1.16–1.72) < 0.001 0.99 (0.80–1.24) 0.951
Pain interference in daily life (any versus none)a 1.26 (0.98–1.63) 0.075 0.85 (0.65–1.12) 0.254
Opioid Rx (ref: none)a
Short term 1.44 (1.08–1.93) 0.012 1.65 (1.43–1.90) < 0.001
Long term 1.06 (0.85–1.34) 0.601 1.00 (0.68–1.48) 0.996
Unhealthy alcohol use, past year (AUDIT-C score ≥ 3 or 4)a 1.18 (0.97–1.44) 0.093 1.04 (0.85–1.29) 0.688
Marijuana use, past year (ref: none)a 1.34 (1.14–1.56) < 0.001 0.85 (0.66–1.09) 0.207
Cocaine use, past year (ref: none)a 2.94 (2.23–3.87) < 0.001 1.74 (1.10–2.76) 0.019
Stimulant use, past year (ref: none)a 5.00 (3.19–7.83) < 0.001 2.12 (1.05–4.27) 0.036
aTime-updated covariates; bat baseline; cany report of new-onset NMUPO prior or concurrent to heroin initiation or censoring;. dusing robust sandwich es-
timator HIV = human immunodeficiency virus; HCV = hepatitis C virus; PTSD= post-traumatic stress disorder; AUDIT = Alcohol Use Disorders Identification
Test; HR = hazard ratio; CI = confidence interval.
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and/or HCV infection). Notably, the rate of heroin initiation
observed in this study, even among those non-exposed to
NMUPO (1.0 per 100 person-years) is higher than the rate
observed among US adults (0.11 per 100 person-years in
2011) [15] Future work is needed to examine the rate of
heroin use and initiation among lower-risk populations of
veterans and veterans not receiving care in the VHA.
Another major limitation of this study was the fact that
there were different versions of the survey question
assessing non-medical use of prescription opioid use. To
mitigate potential information bias arising from the fact
that participants may have misunderstood the question
in the first two versions of the survey (as referring to
medical use of prescription opioids), we adjusted for receipt
of an opioid prescription in all analyses. Thirdly, as with
any survey questions reporting on substance use
behaviors, it is likely that participants under-reported their
previous heroin and NMUPO.We attempted to address this
issue by excluding participants who reported previous
injection drug use and those with an ICD-9 code for opioid
dependence, as well as running sensitivity analyses
excluding participants with hepatitis C. Additionally, we
were able to ascertain only new-onset NMUPO concurrent
or prior to heroin initiation. Finally, differential loss to
follow-up was a potential source of bias in this study. This
was addressed by using inverse probability of censoring
weights to account for possible biases arising from
differential loss to follow-up.
Despite these limitations, our study fills an important
gap in the literature by comparing the demographic,
clinical and substance use characteristics associated with
heroin initiation among US veterans receiving medical
care in the VHA. Identifying why particular veterans
engage in NMUPO, and why a proportion of them then
transition to heroin initiation, are possible next steps in
developing effective NMUPO screening strategies. For
example, previous studies involving college students have
found that the single leading reason for non-medical use
was to relieve pain [54–57]. However, in our final
model, pain interference in daily life was not a signifi-
cant predictor of heroin initiation. Given that the
experiences and the demographics of a veteran popula-
tion are substantially different from young college
students, further research needs to be conducted in
order to elucidate motivations for NMUPO among vet-
erans who receive medical care in the VHA. In sum,
recognizing that NMUPO is a strong risk factor for
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